The XpressCard Point-of-Care Test for Human Neutrophil Gelatinase-Associated Lipocalin Enhances the Prediction of Acute Kidney Injury
Journal of Clinical Medicine · 12.12.2024 · 13 (24) · 7564
DOI: 10.3390/jcm13247564 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 12.12.2024. Verfasst von Kendra B Bufkin und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Management, Economics and Policy, The Graduate School, Augusta University, Augusta, GA 30912, USA. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Augusta University Provost’s office and the Translational Research Program of the Department of Medicine, Medical College of Georgia at Augusta University.
Abstract (Originalsprache)
Background/Objectives: Acute kidney injury (AKI), a common complication in hospitalized patients, is a clinical syndrome with a sudden and reversible decline in kidney function. Within hospitalization, the average incidence rate is 2% to 5%, and 67% of patients admitted to the Intensive Care Unit (ICU) acquire acute kidney injury. There is a pressing need to identify biomarkers that provide early detection to enhance the diagnosis of acute kidney injury. Neutrophil gelatinase-associated lipocalin (NGAL) has been identified as the most promising biomarker for predicting acute kidney injury due to upregulation as early as 2 h before kidney injury.
Methods
Urine samples from 52 adult subjects were utilized to evaluate the accuracy of acute kidney injury diagnosis using the XpressCard for human NGAL. Sensitivity and specificity were calculated to analyze the validity of the NGAL XpressCard’s ability to accurately distinguish between acute and non-acute kidney injury.
Results
The positive and negative predictive values were calculated to determine the prevalence of NGAL and predict the likelihood of diagnosing AKI. Data show that the NGAL XpressCard has a sensitivity and specificity of 59.3% and 95.8% and a positive and negative predictive value of 92.9% and 71.9%, respectively.
Conclusions
The human NGAL XpressCard is effective at predicting AKI in hospitalized patients and correlates with high levels of HbA1c, which is associated with diabetes mellitus. It delivers immediate test results, which can enhance patient care.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Health Management, Economics and Policy, The Graduate School, Augusta University, Augusta, GA 30912, USA.
ORCID-Profile: Jeane Silva
Förderung
- Augusta University Provost’s office and the Translational Research Program of the Department of Medicine, Medical College of Georgia at Augusta University
Zitieren
APA
Bufkin, K. B., & Silva, J. (2024). The XpressCard Point-of-Care Test for Human Neutrophil Gelatinase-Associated Lipocalin Enhances the Prediction of Acute Kidney Injury. Journal of Clinical Medicine, 13(24), 7564. https://doi.org/10.3390/jcm13247564
Vancouver
Bufkin KB, Silva J. The XpressCard Point-of-Care Test for Human Neutrophil Gelatinase-Associated Lipocalin Enhances the Prediction of Acute Kidney Injury. Journal of Clinical Medicine. 2024;13(24):7564. doi:10.3390/jcm13247564
BibTeX
@article{Bufkin2024,
author = {Bufkin, Kendra B and Silva, Jeane},
title = {The XpressCard Point-of-Care Test for Human Neutrophil Gelatinase-Associated Lipocalin Enhances the Prediction of Acute Kidney Injury},
journal = {Journal of Clinical Medicine},
year = {2024},
volume = {13},
number = {24},
pages = {7564},
doi = {10.3390/jcm13247564}
}
EUVIMED